Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Neurology and Therapy
Published in: Neurology and Therapy 2/2019

Open Access 01-12-2019 | Schizophrenia | Commentary

Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia

Authors: Afzal Javed, Holger Arthur, Logos Curtis, Lars Hansen, Sofia Pappa

Published in: Neurology and Therapy | Issue 2/2019

Login to get access

Abstract

Introduction

Lurasidone is an atypical antipsychotic that was approved in Europe in 2014 for the treatment of schizophrenia in adults aged ≥ 18 years. Clinical experience with lurasidone in Europe is currently limited, and there is therefore a need to provide practical guidance on using lurasidone for the treatment of adults with schizophrenia.

Methods

A panel of European psychiatrists with extensive experience of prescribing lurasidone was convened to provide recommendations on using lurasidone to treat adults with schizophrenia.

Results

Extensive evidence from clinical trials and the panel’s clinical experience suggest that lurasidone is as effective as other atypical agents, with the possible exception of clozapine. Lurasidone is associated with a lower propensity for metabolic side effects (in particular, weight gain) and hyperprolactinaemia than most other atypical antipsychotics and has a relatively benign neurocognitive side effect profile. Patients switching to lurasidone from another antipsychotic may experience weight reduction and/or improvements in the ability to focus/concentrate. Most side effects with lurasidone (such as somnolence) are transitory, easily managed and/or ameliorated by dose adjustment. Akathisia and extrapyramidal symptoms may occur in a minority of patients, but these can be managed effectively with dose adjustment, adjunctive therapy and/or psychosocial intervention.

Conclusions

Given the crucial importance of addressing the physical as well as mental healthcare needs of patients, lurasidone is a rational therapeutic choice for adults with schizophrenia, both in the acute setting and over the long term.

Funding

Sunovion Pharmaceuticals Europe Ltd.
Appendix
Available only for authorised users
Literature
1.
Hasan A, Falkai P, Wobrock T, et al.; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13:318–78.PubMedCrossRef
2.
Hasan A, Falkai P, Wobrock T, et al.; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14:2–44.PubMedCrossRef
3.
Lehman AF, Lieberman JA, Dixon LB, et al.; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, 2nd edn. Am J Psychiatry. 2004;161[Suppl 2]:1–56.PubMed
4.
5.
Barnes TR, Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25:567–620.PubMedCrossRef
6.
Cooper SJ, Reynolds GP; With expert co-authors (in alphabetical order):, Barnes T, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016;30:717–48.PubMedCrossRef
7.
Leucht S, Leucht C, Huhn M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174:927–42.PubMedCrossRef
8.
Lieberman JA, Stroup TS, McEvoy JP, et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–23.PubMedCrossRef
9.
Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079–87.PubMedCrossRef
10.
Miyamoto S, Miyake N, Jarskog LF, et al. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17:1206–27.PubMedCrossRef
11.
Citrome L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol. 2017;37:138–47.PubMedCrossRef
12.
13.
14.
Stahl SM. Stahl’s essential pharmacotherapy: neuroscientific basis and practical applications, 4th edn. Cambridge: Cambridge University Press; 2013.
15.
Greenberg WM, Citrome L. Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature. Clin Pharmacokinet. 2017;56:493–503.PubMedCrossRef
16.
Kim DH, Maneen MJ, Stahl SM. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics. 2009;6:78–85.PubMedPubMedCentralCrossRef
17.
Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–77.PubMedPubMedCentralCrossRef
18.
Preskorn S, Ereshefsky L, Chiu YY, et al. Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies. Hum Psychopharmacol. 2013;28:495–505.PubMedCrossRef
19.
Ogasa M, Kimura T, Nakamura M, et al. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl). 2013;225:519–30.PubMedCrossRef
20.
Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70:829–36.PubMedCrossRef
21.
Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47:670–7.PubMedCrossRef
22.
Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168:957–67.PubMedCrossRef
23.
Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013;145:101–9.PubMedCrossRef
24.
Stahl SM, Cucchiaro J, Simonelli D, et al. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry. 2013;74:507–15.PubMedCrossRef
25.
Loebel A, Cucchiaro J, Xu J, et al. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013;147:95–102.PubMedCrossRef
26.
Tandon R, Cucchiaro J, Phillips D, et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. J Psychopharmacol. 2016;30:69–77.PubMedPubMedCentralCrossRef
27.
Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012;27:165–76.PubMedCrossRef
28.
29.
Bruijnzeel D, Yazdanpanah M, Suryadevara U, et al. Lurasidone in the treatment of schizophrenia: a critical evaluation. Expert Opin Pharmacother. 2015;16:1559–65.PubMedCrossRef
30.
Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68[Suppl 1]:20–7.PubMed
31.
Dayabandara M, Hanwella R, Ratnatunga S, et al. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231–41.PubMedPubMedCentralCrossRef
32.
33.
Peuskens J, Pani L, Detraux J, et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28:421–53.PubMedPubMedCentral
34.
de Boer MK, Castelein S, Wiersma D, et al. The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings. Schizophr Bull. 2015;41:674–86.PubMedPubMedCentralCrossRef
35.
Longden E, Read J. Assessing and reporting the adverse effects of antipsychotic medication: a systematic review of clinical studies, and prospective, retrospective, and cross-sectional research. Clin Neuropharmacol. 2016;39:29–39.PubMedCrossRef
36.
Velligan DI, Sajatovic M, Hatch A, et al. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449–68.PubMedPubMedCentralCrossRef
37.
Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72:41–51.PubMedCrossRef
38.
Green MF, Llerena K, Kern RS. The “Right Stuff” revisited: what have we learned about the determinants of daily functioning in schizophrenia? Schizophr Bull. 2015;41:781–5.PubMedPubMedCentralCrossRef
39.
Nuechterlein KH, Subotnik KL, Green MF, et al. Neurocognitive predictors of work outcome in recent-onset schizophrenia. Schizophr Bull. 2011;37(Suppl 2):S33–40.PubMedPubMedCentralCrossRef
40.
Harvey PD, Ogasa M, Cucchiaro J, et al. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res. 2011;127:188–94.PubMedCrossRef
41.
Harvey PD, Siu CO, Hsu J, et al. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol. 2013;23:1373–82.PubMedCrossRef
42.
Rajagopalan K, Wade S, Meyer N, Loebel A. Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis. Curr Med Res Opin. 2017;33:813–20.PubMedCrossRef
43.
Osborne IJ, Mace S, Taylor D. A prospective year-long follow-up of lurasidone use in clinical practice: factors predicting treatment persistence. Ther Adv Psychopharmacol. 2018;8:117–25.PubMedPubMedCentralCrossRef
44.
Loebel A, Silva R, Goldman R, et al. Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study. J Clin Psychiatry. 2016;77:1672–80.PubMedCrossRef
45.
Holloman LC, Marder SR. Management of acute extrapyramidal effects induced by antipsychotic drugs. Am J Health Syst Pharm. 1997;54:2461–77.PubMedCrossRef
46.
Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf. 2005;28:191–208.PubMedCrossRef
47.
48.
49.
Poyurovsky M, Epshtein S, Fuchs C, et al. Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study. J Clin Psychopharmacol. 2003;23:305–8.PubMedCrossRef
50.
Hansen LK, L’allemand T, Thiry F, et al. Structured relaxation in the treatment of akathisia: case series. Neuropsychiatr Dis Treat. 2010;6:269–71.PubMedPubMedCentralCrossRef
51.
Taylor DM, Barnes TRE, Young AH. The maudsley prescribing guidelines in psychiatry, 13th edn. Oxford: Wiley Blackwell; 2018.
Metadata
Title
Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia
Authors
Afzal Javed
Holger Arthur
Logos Curtis
Lars Hansen
Sofia Pappa
Publication date
01-12-2019
Publisher
Springer Healthcare
Published in
Neurology and Therapy / Issue 2/2019
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-019-0138-z

Other articles of this Issue 2/2019

Neurology and Therapy 2/2019 Go to the issue

Original Research

Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital

Review

Deep Learning and Neurology: A Systematic Review

Commentary

Adapting the Goal Attainment Approach for Major Depressive Disorder

Acknowledgement

Acknowledgement to Authors, Referees and Readers 2019

Review

Cognitive Fatigability Interventions in Neurological Conditions: A Systematic Review

Original Research

Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing–Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II Trials